Interaction of Shiga toxin 2 with complement regulators of the factor H protein family

Molecular Immunology

Volumn 58, Issue 1, 2014, Pages 77-84

  Poolpol, Kulwara ^a   Orth Höller, Dorothea ^a   Speth, Cornelia ^a   Zipfel, Peter F ^b   Skerka, Christine ^b   de Córdoba, Santiago Rodriguez ^c   Brockmeyer, Jens ^d   Bielaszewska, Martina ^d   Würzner, Reinhard ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b HANS KNÖLL INSTITUTE   (Germany)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^d UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Complement regulatory proteins; Factor H; Factor H like protein 1; Factor H related protein 1; Hemolytic uremic syndrome; Shiga toxin

Indexed keywords

COMPLEMENT FACTOR H; COMPLEMENT FACTOR H RELATED PROTEIN 1; FACTOR H LIKE PROTEIN 1; UNCLASSIFIED DRUG; VEROTOXIN 2;

ALLOTYPE; AMINO ACID SEQUENCE; ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; ENTEROHEMORRHAGIC ESCHERICHIA COLI; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION;

AHUS; ATYPICAL HUS; COMPLEMENT REGULATORY PROTEINS; EHEC; ENTEROHEMORRHAGIC ESCHERICHIA COLI; FACTOR H; FACTOR H-LIKE PROTEIN 1; FACTOR H-RELATED PROTEIN 1; FACTOR I; FH; FHL-1; FHR-1; FI; HEAT-INACTIVATED STX; HEMOLYTIC UREMIC SYNDROME; HI-STX; HUS; MCP; MEMBRANE COFACTOR PROTEIN; SCRS; SHIGA TOXIN; SHORT CONSENSUS REPEATS; STX; TCC; TERMINAL COMPLEMENT COMPLEX;

AMINO ACID SEQUENCE; BINDING SITES; BLOOD PROTEINS; COMPLEMENT C3B INACTIVATOR PROTEINS; COMPLEMENT FACTOR H; ENTEROHEMORRHAGIC ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HEMOLYTIC-UREMIC SYNDROME; HUMANS; PROTEIN BINDING; SHIGA TOXIN 2;

EID: 84889579190     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2013.11.009     Document Type: Article

References (35)

1. Abarrategui-Garrido C., Martinez-Barricarte R., Lopez-Trascasa M., de Cordoba S.R., Sanchez-Corral P. Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome. Blood 2009, 114:4261-4271.
2. Bauwens A., Betz J., Meisen I., Kemper B., Karch H., Muthing J. Facing glycosphingolipid-Shiga toxin interaction: dire straits for endothelial cells of the human vasculature. Cell Mol. Life Sci. 2013, 70:425-457.
3. Benz M.R., Schmid H., Heinen S., Lange-Sperandio B., Hoefele J., Sitter T., Zipfel P.F., Weber L.T. Different factor H-related protein patterns in siblings with typical hemolytic uremic syndrome. Pediatr. Nephrol. 2011, 26:1345-1347.
4. Ehrlenbach S., Rosales A., Posch W., Wilflingseder D., Hermann M., Brockmeyer J., Karch H., Satchell S.C., Würzner R., Orth-Höller D. Shiga toxin 2 reduces complement inhibitor CD59 expression on human renal tubular epithelial and glomerular endothelial cells. Infect. Immun. 2013, 81:2678-2685.
5. Endo Y., Tsurugi K., Yutsudo T., Takeda Y., Ogasawara T., Igarashi K. Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins. Eur. J. Biochem. 1988, 171:45-50.
6. Friedrich A.W., Bielaszewska M., Zhang W.L., Pulz M., Kuczius T., Ammon A., Karch H. Escherichia coli harboring Shiga toxin 2 gene variants: frequency and association with clinical symptoms. J. Infect. Dis. 2002, 185:74-84.
7. Giannakis E., Jokiranta T.S., Male D.A., Ranganathan S., Ormsby R.J., Fischetti V.A., Mold C., Gordon D.L. A common site within factor H SCR 7 responsible for binding heparin, C-reactive protein and streptococcal M protein. Eur. J. Immunol. 2003, 33:962-969.
8. Goicoechea de J.E., Caesar J.J., Malik T.H., Patel M., Colledge M., Johnson S., Hakobyan S., Morgan B.P., Harris C.L., Pickering M.C., Lea S.M. Dimerization of complement factor H-related proteins modulates complement activation in vivo. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:4685-4690.
9. Heinen S., Hartmann A., Lauer N., Wiehl U., Dahse H.M., Schirmer S., Gropp K., Enghardt T., Wallich R., Halbich S., Mihlan M., Schlotzer-Schrehardt U., Zipfel P.F., Skerka C. Factor H-related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation. Blood 2009, 114:2439-2447.
10. Hellwage J., Kuhn S., Zipfel P.F. The human complement regulatory factor-H-like protein 1, which represents a truncated form of factor H, displays cell-attachment activity. Biochem. J. 1997, 326(Pt 2):321-327.
11. Jozsi M., Oppermann M., Lambris J.D., Zipfel P.F. The C-terminus of complement factor H is essential for host cell protection. Mol. Immunol. 2007, 44:2697-2706.
12. Jozsi M., Licht C., Strobel S., Zipfel S.L., Richter H., Heinen S., Zipfel P.F., Skerka C. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood 2008, 111:1512-1514.
13. Karch H., Tarr P.I., Bielaszewska M. Enterohaemorrhagic Escherichia coli in human medicine. Int. J. Med. Microbiol. 2005, 295:405-418.
14. Kopp A., Strobel S., Tortajada A., Rodriguez de C.S., Sanchez-Corral P., Prohaszka Z., Lopez-Trascasa M., Jozsi M. Atypical hemolytic uremic syndrome-associated variants and autoantibodies impair binding of factor h and factor h-related protein 1 to pentraxin 3. J. Immunol. 2012, 189:1858-1867.
15. Kuhn S., Skerka C., Zipfel P.F. Mapping of the complement regulatory domains in the human factor H-like protein 1 and in factor H1. J. Immunol. 1995, 155:5663-5670.
16. Male D.A., Ormsby R.J., Ranganathan S., Giannakis E., Gordon D.L. Complement factor H: sequence analysis of 221kb of human genomic DNA containing the entire fH, fHR-1 and fHR-3 genes. Mol. Immunol. 2000, 37:41-52.
17. Morigi M., Galbusera M., Gastoldi S., Locatelli M., Buelli S., Pezzotta A., Pagani C., Noris M., Gobbi M., Stravalaci M., Rottoli D., Tedesco F., Remuzzi G., Zoja C. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J. Immunol. 2011, 187:172-180.
18. Noris M., Remuzzi G. Atypical hemolytic-uremic syndrome. N. Engl. J. Med. 2009, 361:1676-1687.
19. Obrig T.G. Escherichia coli Shiga toxin mechanisms of action in renal disease. Toxins (Basel) 2010, 2:2769-2794.
20. Oppermann M., Manuelian T., Jozsi M., Brandt E., Jokiranta T.S., Heinen S., Meri S., Skerka C., Gotze O., Zipfel P.F. The C-terminus of complement regulator Factor H mediates target recognition: evidence for a compact conformation of the native protein. Clin. Exp. Immunol. 2006, 144:342-352.
21. Orth D., Grif K., Khan A.B., Naim A., Dierich M.P., Würzner R. The Shiga toxin genotype rather than the amount of Shiga toxin or the cytotoxicity of Shiga toxin in vitro correlates with the appearance of the hemolytic uremic syndrome. Diagn. Microbiol. Infect. Dis. 2007, 59:235-242.
22. Orth D., Khan A.B., Naim A., Grif K., Brockmeyer J., Karch H., Joannidis M., Clark S.J., Day A.J., Fidanzi S., Stoiber H., Dierich M.P., Zimmerhackl L.B., Würzner R. Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome. J. Immunol. 2009, 182:6394-6400.
23. Poolpol K., Gadner B., Neururer S., Mellmann A., Karch H., Orth D., Würzner R. Do complement factor H 402Y and C7 M allotypes predispose to (typical) haemolytic uraemic syndrome. Int. J. Immunogenet. 2011, 38:383-387.
24. Sanchez-Corral P., Melgosa M. Advances in understanding the aetiology of atypical Haemolytic Uraemic Syndrome. Br. J. Haematol. 2010, 150:529-542.
25. Scheutz F., Teel L.D., Beutin L., Pierard D., Buvens G., Karch H., Mellmann A., Caprioli A., Tozzoli R., Morabito S., Strockbine N.A., Melton-Celsa A.R., Sanchez M., Persson S., O'Brien A.D. Multicenter evaluation of a sequence-based protocol for subtyping Shiga toxins and standardizing Stx nomenclature. J. Clin. Microbiol. 2012, 50:2951-2963.
26. Skerka C., Chen Q., Fremeaux-Bacchi V., Roumenina L.T. Complement factor H related proteins (CFHRs). Mol. Immunol. 2013, 56:170-180.
27. Soames C.J., Sim R.B. Interactions between human complement components factor H, factor I and C3b. Biochem. J. 1997, 326(Pt 2):553-561.
28. Speth C., Würzner R., Stoiber H., Dierich M.P. Complement;. Fundamental Immunology 2008, 1047-1078. Lippincott, Philadelphia. W.E. Paul (Ed.).
29. Stahl A.L., Sartz L., Karpman D. Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Blood 2011, 117:5503-5513.
30. Tarr P.I., Gordon C.A., Chandler W.L. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005, 365:1073-1086.
31. Thurman J.M., Marians R., Emlen W., Wood S., Smith C., Akana H., Holers V.M., Lesser M., Kline M., Hoffman C., Christen E., Trachtman H. Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin. J. Am. Soc. Nephrol. 2009, 4:1920-1924.
32. Tortajada A., Yebenes H., Abarrategui-Garrido C., Anter J., Garcia-Fernandez J.M., Martinez-Barricarte R., Alba-Dominguez M., Malik T.H., Bedoya R., Cabrera P.R., Lopez T.M., Pickering M.C., Harris C.L., Sanchez-Corral P., Llorca O., Rodriguez de C.S. C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation. J. Clin. Invest. 2013, 123:2434-2446.
33. Zhang W., Bielaszewska M., Pulz M., Becker K., Friedrich A.W., Karch H., Kuczius T. New immuno-PCR assay for detection of low concentrations of shiga toxin 2 and its variants. J. Clin. Microbiol. 2008, 46:1292-1297.
34. Zipfel P.F., Skerka C. Complement regulators and inhibitory proteins. Nat. Rev. Immunol. 2009, 9:729-740.
35. Zipfel P.F., Skerka C., Hellwage J., Jokiranta S.T., Meri S., Brade V., Kraiczy P., Noris M., Remuzzi G. Factor H family proteins: on complement, microbes and human diseases. Biochem. Soc. Trans. 2002, 30:971-978.